SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending following its recent licensing deal and talent acquisition from AI chip startup Groq, a move widely seen to bolster its AI inference capabilities. The community is sharply divided, with bulls viewing it as a strategic expansion cementing NVIDIA's leadership, while bears critique it as an overpriced, desperate maneuver amidst a shifting AI hardware landscape and intensifying competition. This deal fuels intense debate over the company's long-term dominance beyond AI training.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs and upcoming Chinese export restrictions. This rally is further fueled by booming industrial demand from EV batteries, solar, and AI data centers, sparking community debate over a potential 'silver squeeze' versus an impending sharp pullback.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is generating significant buzz following multiple analyst upgrades and heightened anticipation for potential partnership announcements, especially at the upcoming CES event. The community is actively debating the stock's trajectory, with many accumulating shares based on conviction in its agentic voice AI technology and substantial contract backlog, while others express frustration over recent underperformance and insider selling.

Boundless is a universal protocol that brings ZK to every chain. Using Boundless, developers can create expressive, high-throughput applications that bypass traditional block size/gas limits.  Developers submit proof requests and provers compete to fulfill them, earning direct rewards and protocol-level incentives through proof of verifiable work.  By abstracting away the complexity of proof generation, aggregation, and onchain settlement, Boundless allows developers to build without worrying about underlying infrastructure, while provers provide strong liveness guarantees, censorship-resistance, and continuously improve the cost curve driven by open market dynamics.  This architecture decouples execution from consensus and introduces a new paradigm for verifiable computing. As the number of Boundless prover nodes grows, the total capacity of the protocol increases, scaling compute across every chain.

Boundless

ZKC is trending with the launch of its new data availability layer, positioning itself as a crucial Ethereum scaling solution and competitor to Celestia. Community discussion emphasizes strong expectations for a significant reversal and substantial upside, with many viewing it as a prime opportunity after recent price action.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Bitcoin is a major talking point with widespread options activity and varied community sentiment as institutional engagement continues to grow, evidenced by major financial platforms embracing crypto ETFs. This interest fuels debates about its resilience and potential for significant price movements, juxtaposed with concerns over market volatility and broader economic influences.

LendingClub Corp. engages in the operations of digital marketplace bank. It operates through the LendingClub Bank and LendingClub Corporation (Parent Only) segments. The LendingClub Bank segment involves the provision of full complement of financial products and solutions, loans, leases, and deposits. The LendingClub Corporation (Parent Only) segment includes the holding company legal entity. The company was founded by Renaud Laplanche and Soulaiman Htite in 2006 and is headquartered in San Francisco, CA.

LendingClub Corp

LendingClub is trending amidst recent analyst upgrades, a new $100 million share repurchase program, and consecutive earnings beats for Q2 and Q3. The community is actively discussing strategic initiatives like expanding into home improvement loans and anticipating future Fed rate cuts, which are expected to bolster the company's financial performance. Despite some investor frustration over its conservative growth, LC's strong balance sheet and high institutional ownership are frequently cited as solid long-term value propositions in the fintech sector.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is experiencing a significant surge following FDA approval of YARTEMLEA, marking it as the first and only approved therapy for transplant-associated thrombotic microangiopathy. Community sentiment is overwhelmingly bullish, anticipating a substantial short squeeze and massive revaluation, citing the drug's potential in a high-need market with no competition. Investors are also factoring in the company's strengthened financial position, including a multi-billion dollar partnership with Novo Nordisk, as key drivers for future growth.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

SQD is experiencing heightened community interest and buying pressure, primarily driven by its acquisition by Rezolve AI and the anticipated release of Tokenomics 2.0. Traders are actively discussing its foundational utility as a decentralized blockchain data platform supporting numerous blockchains, eyeing its potential for a substantial rally.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

BITO is a focal point of conversation as investors anticipate its substantial monthly dividend, with many actively buying on recent dips and viewing current volatility as an accumulation opportunity. The community widely discusses the ETF's dividend payout in relation to its price movements around the ex-dividend date, while maintaining a long-term bullish outlook on Bitcoin's potential for future highs amid ongoing institutional adoption.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF (SMCX) is trending amidst high volatility as the community aggressively debates its potential for rapid gains, driven by Super Micro Computer's (SMCI) role in AI infrastructure and partnerships. While many are 

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Marex Group plc Takes $3.67 Million Position in Denali Therapeutics Inc. $DNLI

Marex Group plc acquired a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the second quarter, according to the company in its most recent disclosure with the...

Camber Capital Management LP Has $5.60 Million Position in Denali Therapeutics Inc. $DNLI

Camber Capital Management LP cut its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 68.0% in the second quarter, according to its most recent Form 13F filing with the Securities...

Wedbush Issues Pessimistic Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price

Wedbush lowered their target price on Denali Therapeutics from $31.00 to $30.00 and set an "outperform" rating on the stock in a research report on Thursday...

Denali Therapeutics (NASDAQ:DNLI) Shares Gap Down - Here's What Happened

Denali Therapeutics (NASDAQ:DNLI) Shares Gap Down - Here's What Happened...

Marshall Wace LLP Sells 783,172 Shares of Denali Therapeutics Inc. $DNLI

Marshall Wace LLP lessened its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 35.8% during the second quarter, according to the company in its most recent filing with...

BTIG Research Reiterates Buy Rating for Denali Therapeutics (NASDAQ:DNLI)

BTIG Research restated a "buy" rating and issued a $32.00 price objective on shares of Denali Therapeutics in a research note on Friday...

3,947,387 Shares in Denali Therapeutics Inc. $DNLI Acquired by Norges Bank

Norges Bank purchased a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and...

Denali Enters Into a $275M Funding Deal With Royalty Pharma

DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.

Schroder Investment Management Group Purchases 94,744 Shares of Denali Therapeutics Inc. $DNLI

Schroder Investment Management Group increased its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 32.5% during the 2nd quarter, according to the company in its most...

Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of "Buy" from Brokerages

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has been assigned a consensus recommendation of "Buy" from the sixteen ratings firms that are currently covering the stock, MarketBeat.com...

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Current Price	$16.99
Prev Close	$16.81
Open	$16.90
Dividend Yield	0.00%
50-Day Moving Average	$17.22
Beta	1.57
Avg. Volume	1.44M
PE Ratio	-5.84

52-Week High	$24.35
52-Week Low	$10.57
Market Capitalization	$2.65B
EPS (Annual)	-$2.57
Price to Book	2.69
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

DNLI
Denali Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DNLI News

DNLIDenali Therapeutics Inc